WST · XBRL financial data

West Pharmaceutical Services financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (WST's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	2,147	2,832	2,887	—	—	—
Revenue from contracts with customers	2,147	2,832	2,887	2,950	2,893	3,074
Cost of goods and services sold	1,379	1,656	1,751	1,821	1,895	1,970
Gross profit	768	1,176	1,136	1,129	999	1,104
Research and development	47	53	59	68	69	74
Selling, general and administrative	302	363	317	353	339	394
Other operating income (expense)	(1)	(1)	1	0	(1)	(1)
Operating income (loss)	407	752	734	676	570	585
Interest expense	8	8	8	9	3	1
Other income (expense)	1	4	(51)	3	(1)	(1)
Income tax expense (benefit)	73	107	115	122	108	122
Net income (loss)	346	662	586	593	493	494
Earnings per share, basic USD per share	4.68	8.89	7.87	7.98	6.75	6.83
Earnings per share, diluted USD per share	4.57	8.67	7.73	7.88	6.69	6.79
Weighted average shares, basic millions of shares	74	74	74	74	73	72
Weighted average shares, diluted millions of shares	76	76	76	75	74	73

Fiscal years (WST's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	616	763	894	854	485	791
Accounts receivable	385	489	507	512	553	574
Inventory	321	378	415	435	377	444
Total current assets	1,374	1,742	1,920	1,936	1,538	1,978
Property and equipment, net	943	1,058	1,158	1,413	1,582	1,726
Right-of-use asset	68	69	104	99	105	117
Goodwill	111	110	107	109	106	110
Total assets	2,794	3,314	3,617	3,830	3,643	4,270
Accounts payable	213	232	215	242	239	254
Accrued liabilities	—	—	—	—	—	39
Current portion of long-term debt	2	44	2	134	0	0
Total current liabilities	503	594	519	672	550	655
Long-term debt	253	209	207	73	203	203
Lease liability, non-current	60	63	93	85	82	96
Total liabilities	939	978	932	949	961	1,094
Retained earnings	1,847	2,457	2,988	3,523	3,957	4,375
Total stockholders' equity	1,855	2,335	2,685	2,881	2,682	3,176
Total liabilities and equity	2,794	3,314	3,617	3,830	3,643	4,270
Common shares outstanding (cover page) millions of shares	74	74	74	73	72	72

Fiscal years (WST's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	346	662	586	593	493	494
Stock-based compensation	34	38	24	23	19	24
Depreciation and amortization	109	122	121	137	155	171
Net cash from operating activities	473	584	724	777	653	755
Purchases of property and equipment	174	253	285	362	377	286
Net cash from investing activities	(180)	(253)	(288)	(369)	(379)	(286)
Share repurchases	116	137	203	438	561	134
Dividends paid	48	51	54	57	59	61
Repayments of long-term debt	0	0	1	2	169	0
Net cash from financing activities	(137)	(168)	(294)	(460)	(623)	(185)
Net change in cash	176	147	132	(40)	(369)	307

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	—	Q1 FY26 10-QDec 27, 2025
Solventum	403	2,209	227*	170.2M	—	Q2 FY26 10-QJun 30, 2026
Medline	2,327	7,685	715*	not reported	—	Q2 FY26 10-QJun 27, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
Align Technology	1,103	1,056	193*	71.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.